HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:3/30/2015)... (PRWEB) March 30, 2015 “ iCareTech ” ... Report, which takes a look at the latest and coolest ... NewsWatch special reporter and technology expert, conducted the review and ... band that’s dedicated to the medical and health fields. , ... of conversation over the past couple of years. Well, at ...
(Date:3/30/2015)... On March 11, 2015, Elle Magazine, in an article ... new treatment options for dealing with stubborn, unwanted fat. Two ... product. The other three technologies use devices to deliver ultrasound ... cold ( CoolSculpting ) to kill fat cells. (see: goo.gl/NmaB4q) ... to permanently remove unwanted fat," says Dr. Simon Ourian, Medical ...
(Date:3/30/2015)... March 30, 2015 Healthy, radiant skin ... Pharmacy. The staff of pharmacists is specially trained and ... like acne, eczema and other conditions. , Most people ... patient’s dermatologist and/or PCP to tackle most skin conditions ... Pharmacy has employed specialty-trained pharmacists who have experience in ...
(Date:3/30/2015)... Innovaacom, a leading provider of medical ... it is expanding its services into Asia in 2015. ... the world comes at a time when Asia’s strengthening ... better healthcare. A rapidly growing aging population and changing ... in medicine in Asia. “We are excited to be ...
(Date:3/30/2015)... York, NY (PRWEB) March 30, 2015 ... and other neurological diseases plays an important role in ... led by scientists from the Icahn School of Medicine ... , Neurological diseases have long been associated with inflammation, ... that occurs when immune cells home in to attack ...
Breaking Medicine News(10 mins):Health News:World’s First Medical Intelligent Band was Featured on NewsWatch Television on January 30, 2015 2Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:MedX Pharmacy Offers Skin Care Tips 2Health News:Innovaacom Expands Services and Medical Education Programs into Asia 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 3
(Date:3/30/2015)... 2015  EP Global Communications, Inc. (OTC-PINK: EPGL) In ... opened negotiations with CooperVision, Inc. at $1.1 billion ... ophthalmic technologies. As previously disclosed publicly, CooperVision, Inc. ... contact lens technologies, which has led to several ... industry experts that just one of these newly ...
(Date:3/30/2015)... AUSTIN, Texas , March 30, 2015 ... highlight the My Diabetes Emergency Plan at the 2015 ... encourage you to be prepared to manage your #diabetes ... of Endocrinology (ACE) – the charitable, educational and scientific ... – has joined forces with Lilly Diabetes to share ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research ... announced the addition of the "Computer Aided ... report to their offering. Annual estimates ... through 2020. Also, a six-year historic analysis is ... are derived from primary and secondary research. Company ...
Breaking Medicine Technology:CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B 2CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B 3Preparation Is Personal for Those with Chronic Illnesses 2Preparation Is Personal for Those with Chronic Illnesses 3Preparation Is Personal for Those with Chronic Illnesses 4Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 2Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 3Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 4
Cached News: